8-K ·Filed Apr 2, 2026

WLK

WESTLAKE CORP
NEUTRAL
Impact 3/10
Horizonweeks Processed6mo ago SEC0001193125-26-139007
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

Monitor for any changes in segment performance or strategy under new leadership, but no immediate trading implications. The orderly transition and retention of Buesinger as advisor reduce execution risk.

DirectionNeutral
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d ⚠ clustered
WLK ▼ -37.32% at T+60d
NEUTRAL call ✗ call lost -37.32% · α vs SPY -50.31% · entry $119.21 → $74.72
Entry anchored
Apr 1, 03:59 PM ET
via exchange tick
T+1d
+0.27%
call +0.27% · α -0.21%
$119.53
settled 6mo ago
T+5d
-0.71%
call -0.71% · α -4.33%
$118.37
settled 6mo ago
T+20d
-3.30%
call -3.30% · α -13.17%
$115.28
settled 5mo ago
T+60d
-37.32%
call -37.32% · α -50.31%
$74.72
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

Westlake Corp announced the retirement of Executive Vice President Robert F. Buesinger, who transitions to Special Advisor, and the appointment of Brian Powers as Senior Vice President and head of the Performance & Essential Materials segment. This is a planned leadership transition with a named successor, reducing disruption risk.

Key Facts

  • Robert F. Buesinger retires as Executive Vice President and Performance & Essential Materials Segment Head
  • Buesinger transitions to role of Special Advisor to the President, effective April 2, 2026
  • Brian Powers appointed Senior Vice President and Performance & Essential Materials Segment Head, effective April 2, 2026
  • Transition approved by the Board on March 30, 2026

Financial Impact

No immediate financial impact disclosed; leadership transition appears planned with successor in place

Risk Factors

  • Potential strategic shift in the Performance & Essential Materials segment under new leadership
  • Integration risk for Brian Powers into the executive team

Market Snapshot

Exchange
NYSE
Sector
Industrial Organic Chemicals

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-139007
Document: 0001193125-26-139007-index-headers.html0001193125-26-139007
Document: 0001193125-26-139007-index.html0001193125-26-139007
Document: 0001193125-26-139007.txt0001193125-26-139007
15 reports for WLK
Performance horizon
100% Hit rate 5 of 5 directional calls best @ T+60▲ +36.80%Apr 14, 2026
Filters
Rows
Reports for WLK — sortable, filterable
TypeNow
Aug 31, 2026
4w ago
8-K
NEUTRAL ★ 2/10
$74.23 $62.31▼ −16.06%▼ −16.38%$63.50 (−14.46%)
Aug 14, 2026
6w ago
Press Release
NEUTRAL ★ 2/10
$78.21 $70.02▼ −10.47%▼ −8.49%$63.50 (−18.81%)
Aug 4, 2026
8w ago
8-K
BULLISH ★ 6/10
$80.63 $74.23▼ −7.94%▼ −6.70%$63.50 (−21.25%)
Jul 21, 2026
10w ago
Press Release
BEARISH ★ 7/10
$76.22 $77.52▼ −1.71%▲ +0.86%$63.50 (+16.69%)
Jun 15, 2026
15w ago
8-K
NEUTRAL ★ 4/10
$84.33 $77.04▼ −8.64%▼ −8.84%$63.50 (−24.70%)
Jun 14, 2026
15w ago
Institutional Cluster
MIXED ★ 5/10
$87.45 $76.07▼ −13.01%▼ −12.26%$63.50 (−27.39%)
May 5, 2026
21w ago
8-K
BEARISH ★ 7/10
$104.29 $86.83▲ +16.74%▲ +21.70%$63.50 (+39.11%)
Apr 20, 2026
23w ago
8-K
NEUTRAL ★ 4/10
$115.44 $91.46▼ −20.77%▼ −25.69%$63.50 (−44.99%)
Apr 14, 2026
24w ago
8-K
BEARISH ★ 7/10
$117.84 $97.56▲ +17.21%▲ +23.51%$63.50 (+46.11%)
Apr 6, 2026
25w ago
8-K
NEUTRAL ★ 4/10
$119.51 $114.07▼ −4.55%▼ −13.53%$63.50 (−46.87%)
Showing 10 of 15

US Market Status

Market Closed — Opens Mon (64h 9m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access